By Josh White
Date: Wednesday 15 Jul 2026
(Sharecast News) - Johnson & Johnson raised its full-year outlook on Wednesday after second-quarter sales rose 6.6% to $25.31bn, ahead of market expectations, while adjusted earnings increased 4.7% to $2.90 per share.
| Johnson & Johnson agrees to pay £13bn for Switze... | 28-Apr-2011 | The Independent |
| S&N DRIFTS AS BID HOPES SLIP | 19-Apr-2011 | Express & Star |
| J&J asks judge to dismiss kickback case | 08-Oct-2010 | Wall Street Journal |
| Genzyme Again Rejects Sanofi’s Bid | 08-Oct-2010 | New York Times |
| Johnson & Johnson buying vaccine maker Crucell | 07-Oct-2010 | USA Today |
| Currency | US Dollars |
| Share Price | $ 256.94 |
| Change Today | $ -1.72 |
| % Change | -0.67 % |
| 52 Week High | $278.43 |
| 52 Week Low | $185.98 |
| Volume | 2,441,377 |
| Shares Issued | 2,407.94m |
| Market Cap | $618,696m |
| RiskGrade | 87 |
| Time | Volume / Share Price |
| 11:51 | 100 @ $256.94 |
| 11:51 | 200 @ $256.95 |
| 11:51 | 382 @ $256.95 |
| 11:51 | 100 @ $256.95 |
| 11:51 | 100 @ $256.95 |
You are here: research